Citations

Clear

4610 citation(s) found for "Lu, Brian".

Abstract LB-276: Fusion transcripts in breast cancer cell lines and tumors
Thompson, E. Aubrey , Asmann, Yan W. , Necela, Brian M. , Williamson, David, Carr, Jennifer M., Baker, Tiffany R., Schroth, Gary P. , Kocher, Jean‐Pierre , Perez, Edith A. , Kalari, Krishna R.

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: LB-276-LB-276

10.1158/1538-7445.am2011-lb-276 Get It

Abstract The role of fusion gene transcripts such as BRC-ABL1 has been long appreciated in hematopoietic malignancies. Recent evidence from next generation sequencing projects has suggested that gene fusion events and the resultant chimaeric transcripts may be expressed in solid tumors. We have developed a novel bioinformatics analytical pipeline to detect fusion gene transcripts from paired-end mRNA-seq data. The bioinformatics tool used for fusion transcript discovery employs multiple steps of false positive filtering and nominates the fusion transcript candidates with high confidence (approaching 100%). The screening and validation of the fusion candidates were quickly carried out using the recommended primer design regions as one of the outputs of the SnowShoes-FD pipeline. This pipeline was used to analyze the transcriptome of 22 breast cancer cell lines and 9 non-transformed breast cell populations. Fifty-four fusion candidates were nominated, all of which were validated using reverse transcription PCR and Sanger sequencing. Five fusion products were predicted to have a second fusion junction point between two fusion partners. These 54 fusion transcripts consist of 103 partner genes that are involved in cell cycle and/or nuclear receptor signaling. No fusion transcripts were identified from the non-transformed breast cell lines. We subsequently analyzed a panel of primary breast tumors, 8 each HER2+, triple negative, and ER+. Fifteen novel fusion transcript candidates have been nominated. Validation and functional analysis of these candidates is in progress. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-276. doi:10.1158/1538-7445.AM2011-LB-276
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
Tütüncü, Melih , Tang, Junger, Zeid, Nuhad Abou, Kale, Nilüfer , Crusan, D. J., Atkinson, Elizabeth J. , Sıva, Aksel , Pittock, Sean J. , Pirko, Istvan, Lucchinetti, Claudia F. , Noseworthy, John H., Rodriguez, Moses , Weinshenker, Brian G. , Kantarci, Orhun H. , Crusan, Daniel J. , Keegan, B. Mark , Pittock, S J , Weinshenker, Brian G , Rodriguez, Moses , Siva, Aksel

Mayo Clinic

Multiple Sclerosis Journal | June 27, 2012 | Volume: 19 | Issue: 2 | Pages: 188-198

10.1177/1352458512451510 | PMID 22736750 Get It

Background: It is unclear if all patients with relapsing–remitting multiple sclerosis (RRMS) ultimately develop progressive MS. Onset of progressive disease course seems to be age- rather than disease duration-dependent. Some forms of progressive MS (e.g. primary progressive MS (PPMS)) are uncommon in population-based studies. Ascertainment of patients with PPMS from clinic-based populations can facilitate a powerful comparison of age at progression onset between secondary progressive MS (SPMS) and PPMS but may introduce unclear biases. Objective: Our aim is to confirm that onset of progressive disease course is more relevant to the patient’s age than the presence or duration of a pre-progression relapsing disease course in MS. Methods: We studied a population-based MS cohort ( n =210, RRMS n =109, progressive MS n =101) and a clinic-based progressive MS cohort ( n =754). Progressive course was classified as primary (PPMS; n =322), single attack (SAPMS; n =112) and secondary progressive (SPMS; n =421). We studied demographics (chi 2 or t -test), age-of-progression-onset ( t -test) and time to Expanded Disability Status Scale of 6 (EDSS6) (Kaplan–Meier analyses). Results: Sex ratio ( p =0.58), age at progression onset ( p =0.37) and time to EDSS6 ( p =0.16) did not differ between the cohorts. Progression had developed before age 75 in 99% of patients with known progressive disease course; 38% with RRMS did not develop progression by age 75. Age at progression onset did not differ between SPMS (44.9±9.6), SAPMS (45.5±9.6) and PPMS (45.7±10.8). In either cohort, only 2% of patients had reached EDSS6 before onset of progression. Conclusions: Patients with RRMS do not inevitably develop a progressive disease course. Onset of progression is more dependent on age than the presence or duration of a pre-progression symptomatic disease course. Moderate disability is sustained predominantly after the onset of a progressive disease course in MS.
Incidence of Infective Endocarditis Caused by Viridans Group Streptococci Before and After Publication of the 2007 American Heart Association's Endocarditis Prevention Guidelines
Tleyjeh, Imad M. , de, Daniel D. Correa, Anavekar, Nandan S., Lahr, Brian D. , Sohail, M. Rizwan , Steckelberg, James M., Wilson, Walter R. , DeSimone, Daniel C. , Baddour, Larry M. , Sohail, M Rizwan , Tleyjeh, Imad M

Mayo Clinic

Circulation | June 12, 2012 | Volume: 126 | Issue: 1 | Pages: 60-64

10.1161/circulationaha.112.095281 | PMID 22689929 Get It

Background— The American Heart Association published updated guidelines for infective endocarditis (IE) prevention in 2007 that markedly restricted the use of antibiotic prophylaxis in certain at-risk patients undergoing dental and other invasive procedures. The incidence of IE caused by viridans group streptococci (VGS) in the United States after publication of the 2007 American Heart Association guidelines has not been reported. Methods and Results— We performed a population-based review of all definite or possible cases of VGS-IE using the Rochester Epidemiology Project of Olmsted County, Minnesota. Patient demographics and microbiological data were collected for all VGS-IE cases diagnosed from January 1, 1999, through December 31, 2010. We also examined the Nationwide Inpatient Sample hospital discharge database to determine the number of VGS-IE cases included between 1999 and 2009. We identified 22 cases with VGS-IE in Olmsted County over the 12-year study period. Rates of incidence (per 100 000 person-years) during time intervals of 1999–2002, 2003–2006, and 2007–2010 were 3.19 (95% confidence interval, 1.20–5.17), 2.48 (95% confidence interval, 0.85–4.10), and 0.77 (95% confidence interval, 0.00–1.64), respectively ( P =0.061 from Poisson regression). The number of hospital discharges with a VGS-IE diagnosis in the Nationwide Inpatient Sample database during 1999–2002, 2003–2006, and 2007–2009 ranged between 15 318 to 15 938, 16 214 to 17 433, and 14 728 to 15 479, respectively. Conclusions— On the basis of data complete through 2010, there has been no perceivable increase in the incidence of VGS-IE in Olmsted County, Minnesota, since the publication of the 2007 American Heart Association endocarditis prevention guidelines.
Adult Congenital Heart Disease
O’Murchu, Brian, Seward, James B.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 92 | Issue: 12 | Pages: 3574-3574

10.1161/01.cir.92.12.3574 | PMID 8521581 Get It

Closed-Chest Resuscitation in a Cardiac Catheterization Laboratory
Dawson, Brian, Moffitt, Emerson A., Glover, William, Swan, H.J.C.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 25 | Issue: 6 | Pages: 976-984

10.1161/01.cir.25.6.976 | PMID 13884028 Get It

Closed-chest massage and defibrillation were used successfully in the management of six acute cardiac emergencies occurring in a cardiac catheterization laboratory. A modification of the Kouwenhoven method of closed-chest massage was used in infants and small children. It is concluded that open-chest resuscitation is usually unnecessary during cardiac catheterization.
Positional Periodic Alternating Vertical Nystagmus with PCA-Tr Antibodies in Hodgkin Lymphoma
Eggers, Scott D.Z. , Pittock, Sean J. , Shepard, Neil T., Neff, Brian A., Klebig, Robin, Habermann, Thomas M. , Pittock, S J

Mayo Clinic

Neurology | May 17, 2012 | Volume: 78 | Issue: 22 | Pages: 1800-1802

10.1212/wnl.0b013e3182583085 | PMID 22592362 Get It

Review article: current treatment options and management of functional dyspepsia
Lacy, Brian E. , Locke, G. Richard, Bouras, Ernest P., DiBaise, John K. , El‐Serag, Hashem B. , Abraham, Bincy , Moayyedi, Paul , Prather, Charlene M., Talley, Nicholas J. , Howden, Colin W. , Moayyedi, Paul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 17, 2012 | Volume: 36 | Issue: 1 | Pages: 3-15

10.1111/j.1365-2036.2012.05128.x | PMID 22591037 Get It

SummaryBackgroundFunctional dyspepsia (FD), a common functional gastrointestinal disorder, is defined by the Rome III criteria as symptoms of epigastric pain or discomfort (prevalence in FD of 89–90%), postprandial fullness (75–88%), and early satiety (50–82%) within the last 3 months with symptom onset at least 6 months earlier. Patients cannot have any evidence of structural disease to explain symptoms and predominant symptoms of gastroesophageal reflux are exclusionary. Symptoms of FD are non‐specific and the pathophysiology is diverse, which explains in part why a universally effective treatment for FD remains elusive.AimTo present current management options for the treatment of FD (therapeutic gain/response rate noted when available).ResultsThe utility of Helicobacter pylori eradication for the treatment of FD is modest (6–14% therapeutic gain), while the therapeutic efficacy of proton pump inhibitors (PPI) (7–10% therapeutic gain), histamine‐type‐2‐receptor antagonists (8–35% therapeutic gain), prokinetic agents (18–45%), tricyclic antidepressants (TCA) (response rates of 64–70%), serotonin reuptake inhibitors (no better than placebo) is limited and hampered by inadequate data. This review discusses dietary interventions and analyses studies involving complementary and alternative medications, and psychological therapies.ConclusionsA reasonable treatment approach based on current evidence is to initiate therapy with a daily PPI in H. pylori‐negative FD patients. If symptoms persist, a therapeutic trial with a tricyclic antidepressant may be initiated. If symptoms continue, the clinician can possibly initiate therapy with an anti‐nociceptive agent, a prokinetic agent, or some form of complementary and alternative medications, although evidence from prospective studies to support this approach is limited.
Obstetric Complications of Ureteroscopy During Pregnancy
Johnson, Elizabeth B., Krambeck, Amy E. , White, Wesley M. , Hyams, Elias S. , Beddies, John, Marien, Tracy , Shah, Ojas , Matlaga, Brian R., Pais, Vernon M.

Mayo Clinic

Journal of Urology | May 15, 2012 | Volume: 188 | Issue: 1 | Pages: 151-154

10.1016/j.juro.2012.02.2566 | PMID 22591961 Get It

Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis
Kim, Simon P. , Thompson, R. Houston, Boorjian, Stephen A. , Weight, Christopher , Han, Leona C., Murad, M. Hassan , Shippee, Nathan D. , Erwin, Patricia J., Costello, Brian A. , Chow, George K. , Leibovich, Bradley C. , Murad, M Hassan , Shippee, Nathan

Mayo Clinic

Journal of Urology | May 14, 2012 | Volume: 188 | Issue: 1 | Pages: 51-57

10.1016/j.juro.2012.03.006 | PMID 22591957 Get It

Interferon beta-1b in secondary progressive MS
Kappos, Ludwig , Weinshenker, Brian G. , Pozzilli, Carlo , Thompson, Alan J. , Beckmann, K., Polman, Chris H. , McFarland, Henry F. , Dahlke, Frank , Weinshenker, Brian G , Pozzilli, Carlo

Mayo Clinic

Neurology | May 13, 2012 | Volume: 63 | Issue: 10 | Pages: 1779-1787

10.1212/01.wnl.0000145561.08973.4f | PMID 15557490 Get It